MPMarta Palombaro

Marta Palombaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Palombaro has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Antonio Gasbarrini

    Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

    2 shared publications
  • Emanuele Rinninella

    UOC di Nutrizione Clinica, Dipartimento di Scienze mediche e chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy

    2 shared publications
  • Esmeralda Capristo

    Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

    2 shared publications
  • Marco Cintoni

    Clinical Nutrition Unit, Department of Medical and Abdominal Surgery and Endocrine-Metabolic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy

    2 shared publications
  • Maria Cristina Mele

    UOC di Nutrizione Clinica, Dipartimento di Scienze mediche e chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy

    2 shared publications
  • Pauline Raoul

    Clinical Nutrition Unit, Department of Medical and Abdominal Surgery and Endocrine-Metabolic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy

    2 shared publications

Latest Publications

  • Open Access

    Omega-3 Polyunsaturated Fatty Acids in Cancer Cachexia and Inflammation: Mechanisms and Delivery Innovations

    by Marco Cintoni, Elena Leonardi, Elisabetta Meo, Pauline Celine Raoul, Marta Palombaro, Emanuele Rinninella, Lucia Parroni, Esmeralda Capristo, Antonio Gasbarrini, Maria Cristina Mele

    Cancer-associated cachexia and chronic systemic inflammation remain among the most challenging complications in oncology, impairing prognosis, treatment tolerability, and survival. This narrative review examines the mechanistic rationale and clinical evidence for omega-3 polyunsaturated fatty acids (PUFAs), principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as adjunctive nutritional and metabolic support agents in this setting, drawing on randomized controlled trials, systematic reviews, meta-analyses, and mechanistic studies, alongside the oral, enteral, parenteral, and nanotechnology-based platforms used to deliver these fatty acids. In experimental models, predominantly cancer cell lines and tumor-bearing rodents, EPA and DHA act on multiple oncological processes, including suppression of pro-inflammatory cytokine synthesis, remodeling of the tumor microenvironment, inhibition of tumor cell proliferation, induction of apoptosis, and attenuation of skeletal muscle catabolism via the ubiquitin-proteasome system and the IGF-1/PI3K/Akt/mTOR axis; in patients, the most consistent mechanistic correlate is a reduction in circulating inflammatory biomarkers. Bioavailability varies substantially by molecular form, with re-esterified triglycerides outperforming ethyl esters and emerging micellar and phospholipid nanoformulations achieving markedly higher absorption in pharmacokinetic and preclinical studies. In advanced non-small cell lung cancer with established cachexia, a meta-analysis of small randomized trials suggests that at least 2 g EPA+DHA per day for six weeks or more may yield modest gains in body weight and quality-of-life scores; this signal, however, derives mainly from pooled analyses and has not been consistently reproduced in individual trials, including large negative trials in mixed cancer populations. Across broader oncological populations, reduction in inflammatory biomarkers is the most consistent finding, effects on chemotherapy tolerability are suggestive but of low certainty, and effects on lean mass and overall survival remain inconclusive. Consistent with ESPEN and ESMO guidance, omega-3 PUFAs should be regarded as metabolic and nutritional support within multimodal cachexia care, not as an anticancer treatment. Omega-3 PUFAs are a biologically grounded and potentially useful, but not yet clinically established, intervention in oncological nutrition, but adequately powered trials with harmonized endpoints, standardized formulations, and stratification by cancer type and cachexia stage are still needed to translate this mechanistic signal into definitive therapeutic protocols.

  • Open Access

    Honey and Beehive Products in Oncology: A Comprehensive Review

    by Pauline Celine Raoul, Gabriele Egidi, Marta Palombaro, Ilaria Romeo, Ginevra Del Borrello, Marco Cintoni, Esmeralda Capristo, Emanuele Rinninella, Antonio Gasbarrini, Maria Cristina Mele

    Background: Bee-derived products are rich in bioactive compounds with antioxidant, anti-inflammatory, antimicrobial, and immunomodulatory properties. Interest is growing in their potential role as adjuncts in supportive nutritional oncology, particularly for preventing and managing treatment-related toxicity symptoms in patients receiving chemotherapy and/or radiotherapy. Methods: A systematic search of human and preclinical studies was conducted in PubMed/MEDLINE, Web of Science, and Scopus from January 2000 to December 2025. Search terms combined bee-related product keywords with oncology-related keywords. Eligible studies included in vitro and in vivo preclinical models as well as clinical studies assessing biological properties, clinical outcomes, safety, and issues of product standardization. Results: Preclinical and clinical studies indicate that beehive products reduce oxidative stress, modulate inflammatory signaling pathways, exhibit antimicrobial activity against wound pathogens, and promote tissue repair. Results are most consistent for oral mucositis and for symptom management in head and neck cancer, where some studies report reduced pain, improved mucosal healing, and better nutritional status. Conclusions: This literature review identifies honey and beehive products as promising functional foods for improving oncological patient care. Further large studies are needed, as the evidence is heterogeneous across sample size, product composition, outcome measures, and therapeutic preparations.